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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR BENIGN
INDICATIONS USING UMBILICAL CORD BLOOD UNITS (UCB) THAT
WERE NOT DEPLETED OF RED BLOOD CELLS
Chow, R.1, Jaing, T.-H.2, Tan, P.3, Rosenthal, J.4, Nademanee, A.4,
Karanes, C.4, Graham, M.5, Gjertson, D.6, Petz, L.1 1. StemCyte
International Cord Blood Center, Arcadia, CA; 2. Chung Gung Memo-
rial Hospital, Linko, Taiwan; 3. Mount Elizabeth Hospital, Singapore,
Singapore; 4. City of Hope National Medical Center, Duarte, CA; 5.
University of Arizona Medical Center, Tuscon, AZ; 6. UCLA Medical
Center, Los Angeles, CA.
UCB is an attractive unrelated source for HSCT of benign
indications; however, cell dosage is a critical factor for UCB
HSCT. The red cell depletion (RCD) and post-thaw wash tech-
niques that are widely used incur signiﬁcant nucleated cell loss.
Two strategies to minimize cell loss are to deplete plasma, but not
the red blood cells (PD) during processing, and forego post-thaw
wash. Eighteen thousand racially diverse PD UCB units are now
available on stem cell registries. A retrospective analysis was per-
formed on 28 patients with benign disorders who were trans-
planted with 31 PD UCB units (3 double cords) with 13 thalasse-
mias, 4 AA, 5 WAS, 2 SCID, 2 osteopetrosis, 1 sickle cell disease,
and 1 unspeciﬁed metabolic disorder. Transplant characteristics:
patient median age 4 years old (range 03–27); median weight 16 kg
(range 4.5–43); male 57%; median no. HLA ABDR matches of 4.0
(5–6/6; 7–5/6; 12–4/6; 4–3/6); median pre-freeze TNC dose 7.7
107/kg; median post-thaw TNC dose as reported by TC 7.7 
107/kg; median pre-freeze CD34 dose 3.1  105/kg; transplants
outside of U.S. 68%; non-myeloablative 6%; 25% post-thaw
washed (W), 61% infused without post-thaw wash (NW), 16%
unknown post thaw manipulation. The median time to engraft-
ment for ANC 500 (n  21), platelet 20K (n  20), and 50K (n 
18) are 17.5 days (range 11–41), 48.0 days (range 13–82), and 56.5
days (range 21–96), respectively. No major adverse event was
observed in either the W or the NW group, and the median time
to engraftment for ANC 500, platelet 20 K and 50 K for W versus
NW were 27 versus 12 days, 58 versus 44 days, and 73 versus 53
days, respectively. The unadjusted cumulative incidence (C.I.) of
ANC 500 and platelet 20 K and 50 K engraftment are 89  7%,
89  7%, and 87  8%, respectively. The incidence of reported
grade II acute GVHD was 33%, and none had grade III-IV acute
GVHD. Fifty percent developed limited chronic GVHD (7/14),
and so far only one patient was reported to have extensive chronic
GVHD. With a median follow-up of 356 days (range 93–1100
days), the Kaplan-Meier estimates of 1-year TRM, OS, and dis-
ease-free survival were 11  6%, 89  6%, and 89  6%, respec-
tively. These results demonstrate that HSCT using unrelated PD
UCB can be performed safely and effectively in patients with
benign disorders, and post-thaw washing may delay engraftment of
HSCT using PD UCB.
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Winiarski, J.2, Ringden, O.1 1. Centre for Allogeneic Stem Cell Trans-
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Background: Allogeneic hematopoietic stem cell transplantation
(ASCT) is a possible cure for many inherited disorders. Methods:
We report 20 years’ experience in 71 patients. The disorders
include 7 immuno-deﬁciencies, 21 hematological disorders, 13
histiocytic disorders, 9 mucopoly-saccharoidoses, 7 metachromatic
leukodystrophies (MLD), 3 adrenoleuko-dystrophies (ALD), 2 ad-
renomyeloneuropathy (AMN), 6 patients with Gaucher’s disease, 1
Sandhoff’s disease, and 2 patients with aspartylglucosaminuria.
Their median age was 4 (0–39) years. The donors were 29 HLA-
identical related, 27 matched unrelated (MUD), and 15 HLA
mismatches. Results: In recipients of HLA-identical sibling grafts,
none developed acute GVHD grades II–IV as against 22% in all
others. The overall cumulative incidence of chronic GVHD was
17%. The 5-year survival rates were 93%, 84%, and 46% in
recipients of grafts from HLA-identical siblings, MUD, and HLA-
mismatches, respectively. The overall 10-year survival rate was
69%. All of the surviving patients with immunodeﬁciencies and
hemoglobinopathies are well. Four patients with Hurler’s disease
are also well, apart from skeletal problems. Five patients with
Gaucher’s disease are between 14 and 22 years after the transplant.
Two infants with MLD deteriorated, a girl with the juvenile form
has stable disease and one woman with the adult form has im-
proved. Among 4 survivors with ALD/AMN, 3 are well and 1 has
dementia. Two patients with aspartylglucosaminuria have stable
disease. Conclusions: In patients with inborn errors of metabo-
lism, ASCT gives a high survival rate using HLA-matched donors.
Beneﬁcial effects are seen in those who are transplanted early.
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DEFIBROTIDE FOR THE TREATMENT OF SINUSOIDAL OBSTRUCTION
SYNDROME IN CHILDREN: A SINGLE INSTITUTION’S EXPERIENCE
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Haematology/Oncology, The Hospital for Sick Children, Toronto, ON,
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This retrospective report describes the experience in a single
institution with deﬁbrotide in children with sinusoidal obstruction
syndrome (SOS) following hematopoietic progenitor cell trans-
plant (HPCT). Patients who underwent HPCT between February
1999 and September 2004 and received deﬁbrotide during their
admission were identiﬁed from pharmacy records. Demographic
data and information regarding the clinical course of these patients
were abstracted from the health records. Fourteen children (mean
age: 9.3 years; range 0.4 to 18.1) received deﬁbrotide; 10 were girls.
Most patients underwent HPCT for hematologic malignancies
(8/14) and received matched unrelated donor transplants (8/14).
Conditioning regimens included cyclophosphamide (13/14),
busulphan (7/14), and TBI (5/14). SOS was diagnosed on average
on transplant day 11.4 (&minus4 to 33). Deﬁbrotide was
started on transplant day 17.5 (4 to 40) when the mean prob-
ability of developing severe SOS was 18.1% (0.1–55.3%; N  7).
The mean initial deﬁbrotide dose was 26 mg/kg/day (11 to 40
mg/kg/day); the mean maximum deﬁbrotide dose was 38.2 mg/kg/
day (11 to 81 mg/kg/day). The mean duration of deﬁbrotide
therapy was 16 days (4 to 37 days). Deﬁbrotide was discontinued
due to clinical improvement (9), death (3), drug unavailability (1),
and neurological toxicity (1). Gastrointestinal hemorrhage was
observed in 2 patients during deﬁbrotide therapy. One of these
patients continued deﬁbrotide for a further 12 days; deﬁbrotide
was stopped in the second due to its possible contribution to
neurological symptoms. Intra-cranial hemorrhage was observed in
1 patient during deﬁbrotide therapy. The survival rate to day100
was 79%. Deﬁbrotide appears to be an effective and relatively safe
treatment for children with SOS. Further research must be under-
taken to determine the pharmacokinetic disposition of deﬁbrotide
in children, its optimal dose and its adverse effect proﬁle.
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RAPID AND DURABLE ENGRAFTMENT AFTER UNRELATED CORD
BLOOD TRANSPLANTATION (CBT) FOR CHILDREN WITH TRANSFU-
SION-DEPENDENT THALASSEMIA
Jaing, T.-H.1, Rosenthal, J.2, Chow, R.3 1. Chung Gung Memorial
Hospital, Linko, Taiwan; 2. City of Hope National Medical Center,
Duarte, CA; 3. StemCyte Taiwan National Cord Blood Center, Linko,
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Umbilical cord blood (UCB) is an attractive unrelated source for
hematopoietic stem cell transplantation (HSCT) of thalassemia;
however, cell dosage is a critical factor for CBT. By combining
strategies that maximize cell dose, promising results may be
achieved with unrelated CBT in selected patients. Between Octo-
ber 2003 and September 2005, unrelated CBT was performed after
myeloablative therapy in 10 pediatric patients with transfusion-
dependent thalassemia at Chung Gung Memorial Hospital. All
patients were Pesaro class 1, except for 1 who was class 2. The
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